Chicago Atlantic BDC (LIEN) Q3 2026: Revenue Beats, EPS Falls Short

Chicago Atlantic BDC posted Q3 2026 total investment income of $15.44 million, edging past the $15.42 million consensus by 0.15%. That top-line beat was overshadowed by an earnings shortfall: net investment income per share came in at $0.36, missing the $0.38 estimate by 5.26%.

The culprit was a sharp increase in net expenses, which rose to $7.13 million from $5.58 million in the year-earlier quarter. Heavier credit-facility borrowings pushed interest expense from $338,515 to $1,248,085, and the company did not benefit from an expense limitation agreement that had cushioned results by $230,419 in the prior-year period. Those two forces together compressed net investment income despite strong top-line growth.

On the portfolio side, the picture is notably more robust. Total investments at fair value grew to $399.60 million across 39 companies, up from $334.8 million in Q2 2026, following $72.0 million in new fundings to two borrowers during the quarter. CEO Peter Sack called it a record year for gross originations, with $167.4 million deployed year to date. The weighted average yield on debt investments dipped to 15.5% from 16.0% in Q2, but the entire portfolio remains 100% senior secured with no loans on non-accrual.

Management declared a Q4 2026 regular dividend of $0.34 per share, payable January 15, 2027, to shareholders of record December 31, keeping the payout at the same level it has held for eight consecutive quarters. The company also cited a near-term pipeline of roughly $687 million under evaluation, alongside a $500 million shelf registration that became effective September 30, 2026, to support further portfolio growth.

A pending all-stock merger with affiliate Chicago Atlantic Real Estate Finance is targeted to close in 2027, subject to stockholder approvals and other conditions, with the combined entity expected to surpass $782 million in assets. Rising leverage is a variable to monitor: the debt-to-equity ratio moved to 0.30x from 0.09x in Q2 2026, and available liquidity stood at approximately $6.7 million as of November 11, 2026. The company's concentrated exposure to cannabis lending, which represents 78% of the portfolio, ties its outlook closely to the regulatory environment following the April 2026 rescheduling of medical cannabis.